On November 9, 2008, we published an article and an accompanying editorial on the results of JUPITER, a large randomized trial in which patients without hyperlipidemia who were receiving rosuvastatin had significantly fewer cardiovascular events than did patients receiving placebo. In Clinical Directions, a new interactive feature, we invite you to respond to questions raised by the results of the trial, to contribute your own thoughts, and to read the comments of your peers. Polling and commenting closed on November 26, 2008.